Contract Research

Daedalus can offer the following Research Packages:

1) Introduction to Lysosomal Storage Diseases

2) Emerging Therapies in Lysosomal Storage Diseases

3) Orphan Drug Acquisition Strategies

4) Orphan Disorders Secondary to Hepatitis C Infection

5) Chaperone Therapies

6) Protein Misfolding and Aggregation Disorders

7) Protein Misfolding Disorders and Diseases of Aging

8) Early Support of Academic Rare Disease Drug Development

9) Rare Metabolic Disorders with Perinatal Onset

10) Rare Mitochondrial Disorders and Drugs in Development

11) Rare Neuromuscular Disorders and Drugs in Development

12) Introduction to Rare Endocrine Disorders

13) Rare Hepatic Disorders and Compounds in Development

14) Catecholaminergic Polymorphic Ventricular Tachycardia

15) Immune Modulators with G1S Cell Cycle Inhibition

16) Therapeutic Strategies in Lysosomal Storage Diseases

17) Hematological Cancers Secondary to Hepatitis C Infection

18) Autoimmune Disorders related to Hepatitis C Infection

19) Cirrhosis & Mortality in Successfully Treated Hepatitis C

20) Cancer Risk in Successfully Treated Hepatitis C

21) Generic Drug Firms and Small Molecule Orphan Therapies

22) Emerging Therapies in Solid Organ Transplant

23) Waldenstrom’s Macroglobulinemia with Cold Agglutinin Disease

24) Sustained v. Immediate Release Formulations - More than Convenience

25) Hyper-Activation of the Immune System in Chronic Viral Infection

26) Introduction to Hereditary Angioedema (HAE): Current & Emerging Therapies

27) Drug-Induced Respiratory Depression, Emerging Therapies

28) Complement Inhibition and Orphan Disorders

29) Drug Development Stages and Biopharma Asset Values

30) Orphan Drug Spending Trends Worldwide

31) The Future of Orphan Pricing in Europe and the United States

32) Emerging Liver Fibrosis and Cirrhosis Therapies

33) Reviving Clinical Trial Failures for Orphan Indications

34) Strategies to Optimize Pricing of Generic Drugs Repurposed for Orphan Indications

35) Survey of Orphan Disorders with Commercial Size and Drugs in Development

36) Cortisol Modulation and Orphan Disorder Opportunities

37) Intrapulmonary Benzodiazepines for multiple Orphan Disorders

38) Compounds in Development for Orphan Disorders -- 2013

39) Compounds in Development for Orphan Disorders -- 2014

40) Compounds in Development for Orphan Disorders -- 2015

41) Orphan Disorders of Neurodegeneration

42) Orphan Disorders with a Prominent Seizure Component

43) Emerging Therapies in Multiple Myeloma

44) Hepatitis C and Multiple Myeloma

45) Therapies for Multiple Myeloma patients receiving long-term opioid therapy – a commercial and clinical opportunity

46) Busted Compounds. Inexpensive assets with potential in Orphan Indications